Home » Newsletters » BioWorld Science

BioWorld Science

Sep. 4, 2014

View Archived Issues

Bristol-Myers Squibb designs novel NS5B inhibitors

Palatin and Gedeon Richter sign collaboration and license agreement for bremelanotide in Europe

First results of the X-VERT trial of rivaroxaban in nonvalvular AF presented

Novel anti-NRG-1 MAbs disclosed by MBL

Chinese group divulges novel ALK inhibitors

Enzyme replacement therapy tested in a murine model of human neurofibromatosis type 1

Synergistic activity of neem, karanja and aloe vera in patients with skin injuries

Lilly patents new EP4 receptor antagonists

Novartis designs new IP receptor agonists

Aurigene reports new BTK inhibitors

Phase I study of novel antifungal agent F-901318 begins

Antisense Therapeutics reports efficacy results from phase II acromegaly study of ATL-1103

FDA grants orphan drug status to Genz-682452 for Fabry's disease

Halozyme Therapeutics' PEGPH-20 program receives fast track designation

Iluvien receives marketing authorization in Sweden for chronic diabetic macular edema

Lorus Therapeutics changes name

Sanofi Pasteur reports data from final phase III efficacy study of dengue vaccine candidate

Infinity and AbbVie to develop and commercialize duvelisib in oncology

Tetraphase Pharmaceuticals reports data from phase III trial of eravacycline

XBiotech reports phase III data for Xilonix in colorectal cancer

BMS returns clazakizumab rights to Alder BioPharmaceuticals

ViiV Healthcare receives E.U. marketing authorization for Triumeq

Ryzodeg launched in first country

Cleveland BioLabs clear to submit pre-EUA for entolimod

GeNeuro reports 1-year extension study findings on GNbAC-1 for MS

First volunteers vaccinated in NIAID study of Ebola vaccine